Gilead Sciences Inc
Sentinellis Health Score
8.9/10
$162.0B
$29.4B
17.8x
AI Summary
Gilead discovers, develops, and commercializes medicines for serious diseases where treatment options are limited. Their core business focuses on HIV treatments like Biktarvy and Descovy, hepatitis medications including Epclusa and Vemlidy, and cancer therapies such as Trodelvy and Yescarta. The company also produces AmBisome for fungal infections and Veklury for COVID-19, while actively developing new immunotherapies through partnerships with other biotech firms.
Gilead Sciences is a major biopharmaceutical company that develops and sells medicines for HIV, hepatitis, cancer, and other serious diseases, generating $29.4 billion in annual revenue [Yahoo Finance]. The company recently reported better-than-expected first-quarter 2026 earnings driven by strong HIV drug sales, particularly Biktarvy, though management raised guidance cautiously due to acquisition-related costs [Yahoo Finance]. Gilead maintains solid financial health with strong margins and cash flow, while recent insider selling and strategic debt issuance signal ongoing business evolution [SEC Form 4] [Yahoo Finance].
Gilead is financially healthy with strong profitability, robust cash generation, and manageable debt levels.
Recent News
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report
Yahoo Finance· 2026-05-20Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
Yahoo Finance· 2026-05-18Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer
Yahoo Finance· 2026-05-19Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
Yahoo Finance· 2026-05-18Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?
Yahoo Finance· 2026-05-16Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial
Yahoo Finance· 2026-05-14
Risk Analysis
Opportunities
Full Financials
Executive Team
Unlock the full Gilead Sciences Inc analysis
Create a free account to access the complete AI-generated report with inline citations.
- Risks, opportunities, and red flags with sources
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
Other companies you might find interesting
Same sector (Healthcare) or comparable health.